$ANVS
Annovis Bio, Inc.

2021 Form 10-K Financial Statement

#000155837022002668 Filed on March 02, 2022

View on sec.gov

Income Statement

Concept 2021 2020 Q4 2020
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $6.058M $497.5K $3.586M
YoY Change 68.93% 357.32% 332.4%
% of Gross Profit
Research & Development $8.479M $1.410M $3.054M
YoY Change 177.63% 85.0% 293.43%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $14.54M $1.910M $6.640M
YoY Change 118.93% 119.26% 313.56%
Operating Profit -$14.54M -$6.640M
YoY Change 118.93%
Interest Expense $13.34K $210.00 $47.23K
YoY Change -71.76% -100.32% -139.21%
% of Operating Profit
Other Income/Expense, Net $50.09K $1.178M
YoY Change -95.75%
Pretax Income -$14.49M -$1.705M -$5.462M
YoY Change 165.23% 746.97% 451.18%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$14.49M -$1.705M -$5.462M
YoY Change 165.23% 746.97% 451.18%
Net Earnings / Revenue
Basic Earnings Per Share -$1.90 -$0.87
Diluted Earnings Per Share -$1.90 -$247.2K -$0.87
COMMON SHARES
Basic Shares Outstanding 7.626M 6.309M
Diluted Shares Outstanding 7.626M 6.309M

Balance Sheet

Concept 2021 2020 Q4 2020
SHORT-TERM ASSETS
Cash & Short-Term Investments $45.69M $8.075M $8.075M
YoY Change 465.79% 434021.51% 434021.51%
Cash & Equivalents $45.69M $8.075M $8.075M
Short-Term Investments
Other Short-Term Assets $315.5K $44.67K $44.67K
YoY Change 606.22% 322.21% 322.21%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $46.00M $8.119M $8.119M
YoY Change 466.57% 986.18% 986.18%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $0.00 $0.00 $0.00
YoY Change -100.0% -100.0%
TOTAL ASSETS
Total Short-Term Assets $46.00M $8.119M $8.119M
Total Long-Term Assets $0.00 $0.00 $0.00
Total Assets $46.00M $8.119M $8.119M
YoY Change 466.57% 626.82% 626.82%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $688.1K $341.9K $341.9K
YoY Change 101.27% -72.29% -72.29%
Accrued Expenses $818.4K $236.5K $236.5K
YoY Change 246.03% -69.55% -69.55%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $1.507M $578.4K $578.4K
YoY Change 160.47% -71.24% -71.24%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change -100.0% -100.0%
Other Long-Term Liabilities $0.00 $0.00
YoY Change -100.0% -100.0%
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change -100.0% -100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $1.507M $578.4K $578.4K
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $1.507M $578.4K $578.4K
YoY Change 160.47% -77.9% -77.9%
SHAREHOLDERS EQUITY
Retained Earnings -$14.24M
YoY Change
Common Stock $689.00
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $44.49M $7.541M $7.541M
YoY Change
Total Liabilities & Shareholders Equity $46.00M $8.119M $8.119M
YoY Change 466.57% 626.82% 626.82%

Cashflow Statement

Concept 2021 2020 Q4 2020
OPERATING ACTIVITIES
Net Income -$14.49M -$1.705M -$5.462M
YoY Change 165.23% 746.97% 451.18%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$9.132M -$765.9K -$3.971M
YoY Change 129.98% 1358.12% 733.26%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $46.65M $12.03M
YoY Change 287.63%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 46.74M 0.000 12.04M
YoY Change 288.12% -100.0% 2618.1%
NET CHANGE
Cash From Operating Activities -9.132M -765.9K -3.971M
Cash From Investing Activities
Cash From Financing Activities 46.74M 0.000 12.04M
Net Change In Cash 37.61M -765.9K 8.073M
YoY Change 365.9% 1308.26% -24233.93%
FREE CASH FLOW
Cash From Operating Activities -$9.132M -$765.9K -$3.971M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.90
CY2020 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.87
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
7626278
CY2020 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
6308961
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y4M24D
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P7Y10M24D
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
7626278
CY2020 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
6308961
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.90
CY2020 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.87
CY2021 dei Entity Central Index Key
EntityCentralIndexKey
0001477845
CY2021 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
CY2021 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2021 dei Amendment Flag
AmendmentFlag
false
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Income Tax Examination Penalties And Interest Accrued
IncomeTaxExaminationPenaltiesAndInterestAccrued
0
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
6891608
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
8100570
CY2020Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2020 us-gaap Federal Income Tax Expense Benefit Continuing Operations
FederalIncomeTaxExpenseBenefitContinuingOperations
0
CY2021 us-gaap Federal Income Tax Expense Benefit Continuing Operations
FederalIncomeTaxExpenseBenefitContinuingOperations
0
CY2021 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
0
CY2021 dei Document Type
DocumentType
10-K
CY2021 dei Document Annual Report
DocumentAnnualReport
true
CY2021 dei Document Period End Date
DocumentPeriodEndDate
2021-12-31
CY2021 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2021 dei Document Transition Report
DocumentTransitionReport
false
CY2021 dei Entity File Number
EntityFileNumber
001-39202
CY2021 dei Entity Registrant Name
EntityRegistrantName
Annovis Bio, Inc.
CY2021 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2021 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
26-2540421
CY2021 dei Entity Address Address Line1
EntityAddressAddressLine1
1055 Westlakes Drive, Suite 300
CY2021 dei Entity Address City Or Town
EntityAddressCityOrTown
Berwyn
CY2021 dei Entity Address State Or Province
EntityAddressStateOrProvince
PA
CY2021 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
19312
CY2021 dei City Area Code
CityAreaCode
610
CY2021 dei Local Phone Number
LocalPhoneNumber
727-3913
CY2021 dei Security12b Title
Security12bTitle
Common Stock, par value $0.0001 per share
CY2021 dei Trading Symbol
TradingSymbol
ANVS
CY2021 dei Security Exchange Name
SecurityExchangeName
NYSE
CY2021 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2021 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2021 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2021 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2021 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2021 dei Entity Small Business
EntitySmallBusiness
true
CY2021 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2021 dei Entity Ex Transition Period
EntityExTransitionPeriod
true
CY2021 dei Entity Shell Company
EntityShellCompany
false
CY2021 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2021Q2 dei Entity Public Float
EntityPublicFloat
481819080
CY2022Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
8163923
CY2021 dei Auditor Name
AuditorName
WithumSmith+Brown, PC
CY2021 dei Auditor Location
AuditorLocation
East Brunswick, New Jersey
CY2021 dei Auditor Firm
AuditorFirmId
100
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
45686014
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
8074658
CY2021Q4 anvs Prepaid Expense Security Deposits And Other Assets Current
PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent
315464
CY2020Q4 anvs Prepaid Expense Security Deposits And Other Assets Current
PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent
44676
CY2021Q4 us-gaap Assets Current
AssetsCurrent
46001478
CY2020Q4 us-gaap Assets Current
AssetsCurrent
8119334
CY2021Q4 us-gaap Assets
Assets
46001478
CY2020Q4 us-gaap Assets
Assets
8119334
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
688074
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
341856
CY2021Q4 anvs Accrued Liabilities And Interest And Employee Related Liabilities Current
AccruedLiabilitiesAndInterestAndEmployeeRelatedLiabilitiesCurrent
818440
CY2020Q4 anvs Accrued Liabilities And Interest And Employee Related Liabilities Current
AccruedLiabilitiesAndInterestAndEmployeeRelatedLiabilitiesCurrent
236524
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1506514
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
578380
CY2021Q4 us-gaap Liabilities
Liabilities
1506514
CY2020Q4 us-gaap Liabilities
Liabilities
578380
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2000000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2000000
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
35000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
35000000
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
8100570
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
6891608
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
810
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
689
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
73220361
CY2020Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
21779340
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-28726207
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-14239075
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
44494964
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
7540954
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
46001478
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
8119334
CY2021 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8479031
CY2020 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3054025
CY2021 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6058190
CY2020 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3586196
CY2021 us-gaap Operating Expenses
OperatingExpenses
14537221
CY2021 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
50089
CY2020 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1178174
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-14487132
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-5462047
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-14487132
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-5462047
CY2020 us-gaap Operating Expenses
OperatingExpenses
6640221
CY2021 us-gaap Operating Income Loss
OperatingIncomeLoss
-14537221
CY2020 us-gaap Operating Income Loss
OperatingIncomeLoss
-6640221
CY2020 us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
-26500
CY2021 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
13335
CY2020 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
47225
CY2021 anvs Income From Grants
IncomeFromGrants
36754
CY2020 anvs Income From Grants
IncomeFromGrants
1157449
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.90
CY2020 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.87
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7626278
CY2020 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
6308961
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
-8576400
CY2020 anvs Stock Issued During Period Value Conversion Of Convertible Securities Preferred Stock
StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesPreferredStock
7076952
CY2020 anvs Stock Issued During Period Value Conversion Of Convertible Securities Convertible Promissory Notes
StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesConvertiblePromissoryNotes
672524
CY2020 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
11955795
CY2020 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
9217
CY2020 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
122750
CY2020 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
1742163
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-5462047
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
7540954
CY2021 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
46648413
CY2021 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
95102
CY2021 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
4697627
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-14487132
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
44494964
CY2021 us-gaap Profit Loss
ProfitLoss
-14487132
CY2020 us-gaap Profit Loss
ProfitLoss
-5462047
CY2020 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
129
CY2020 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
396
CY2021 us-gaap Share Based Compensation
ShareBasedCompensation
4697627
CY2020 us-gaap Share Based Compensation
ShareBasedCompensation
1864913
CY2020 us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
-26500
CY2020 anvs Increase Decrease In Grants Receivable
IncreaseDecreaseInGrantsReceivable
-735075
CY2021 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
270788
CY2020 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
34097
CY2021 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
346218
CY2020 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-695660
CY2021 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
581916
CY2020 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-406032
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-9132159
CY2020 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3970823
CY2020 us-gaap Share Based Compensation
ShareBasedCompensation
1864913
CY2021 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
46648413
CY2020 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
12034406
CY2021 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
95102
CY2020 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
9217
CY2021 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
46743515
CY2020 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
12043623
CY2021 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
37611356
CY2020 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
8072800
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
8074658
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1858
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
45686014
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
8074658
CY2020 anvs Conversion Of Redeemable Convertible Preferred Stock To Common Stock
ConversionOfRedeemableConvertiblePreferredStockToCommonStock
7076952
CY2020 anvs Conversion Of Convertible Promissory Notes Including Embedded Derivative To Common Stock
ConversionOfConvertiblePromissoryNotesIncludingEmbeddedDerivativeToCommonStock
672524
CY2021 us-gaap Basis Of Accounting
BasisOfAccounting
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(a) Basis of Presentation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”). Any reference in these notes to applicable guidance is meant </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">to refer to U.S. GAAP as found in the Accounting Standards Codification (“ASC”) and Accounting Standards Update (“ASU”) of the Financial Accounting Standards Board (“FASB”).</p>
CY2021 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(b) Use of Estimates</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, including disclosure of contingent assets and liabilities, at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Due to the uncertainty of factors surrounding the estimates or judgments used in the preparation of the financial statements, actual results may materially vary from these estimates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Significant items subject to such estimates and assumptions include progress towards completion of research and development projects, stock-based compensation expense, grant income and contingent liabilities. Future events and their effects cannot be predicted with certainty; accordingly, accounting estimates require the exercise of judgment. Accounting estimates used in the preparation of these financial statements change as new events occur, as more experience is acquired, as additional information is obtained and as the operating environment changes.</p>
CY2020 anvs Unreimbursed Eligible Costs Incurred During Period
UnreimbursedEligibleCostsIncurredDuringPeriod
0
CY2021 anvs Unreimbursed Eligible Costs Incurred During Period
UnreimbursedEligibleCostsIncurredDuringPeriod
0
CY2020Q4 anvs Grant Award Remaining Amount Available
GrantAwardRemainingAmountAvailable
0
CY2021Q4 anvs Grant Award Remaining Amount Available
GrantAwardRemainingAmountAvailable
0
CY2021Q4 anvs Prepaid Research And Development Expense Current
PrepaidResearchAndDevelopmentExpenseCurrent
232752
CY2021Q4 us-gaap Prepaid Insurance
PrepaidInsurance
29111
CY2020Q4 us-gaap Prepaid Insurance
PrepaidInsurance
26542
CY2021Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
43736
CY2020Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
11690
CY2021Q4 us-gaap Security Deposit
SecurityDeposit
9865
CY2020Q4 us-gaap Security Deposit
SecurityDeposit
6444
CY2021Q4 anvs Prepaid Expense Security Deposits And Other Assets Current
PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent
315464
CY2020Q4 anvs Prepaid Expense Security Deposits And Other Assets Current
PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent
44676
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
352282
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.19
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
810000
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
712768
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
16493
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
105672
CY2020Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
216198
CY2020Q4 anvs Accrued License Payments Current
AccruedLicensePaymentsCurrent
3833
CY2021Q4 anvs Accrued Liabilities And Interest And Employee Related Liabilities Current
AccruedLiabilitiesAndInterestAndEmployeeRelatedLiabilitiesCurrent
818440
CY2020Q4 anvs Accrued Liabilities And Interest And Employee Related Liabilities Current
AccruedLiabilitiesAndInterestAndEmployeeRelatedLiabilitiesCurrent
236524
CY2019Q1 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
26500
CY2021 us-gaap Operating Lease Expense
OperatingLeaseExpense
51760
CY2020 us-gaap Operating Lease Expense
OperatingLeaseExpense
41603
CY2021 us-gaap Loss Contingency New Claims Filed Number
LossContingencyNewClaimsFiledNumber
2
CY2020Q1 anvs Number Of Classes Of Stock Designated
NumberOfClassesOfStockDesignated
2
CY2020Q1 anvs Common Stock And Preferred Stock Shares Authorized
CommonStockAndPreferredStockSharesAuthorized
37000000
CY2020Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2020Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
35000000
CY2020Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2000000
CY2021Q4 anvs Number Of Votes For Each Share Of Common Stock
NumberOfVotesForEachShareOfCommonStock
1
CY2020 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
3.46
CY2021 us-gaap Share Based Compensation
ShareBasedCompensation
4697627
CY2020 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
48435
CY2020 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.19
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
2381
CY2020 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
0.14
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1111466
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
2.57
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
538095
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
33.78
CY2021 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
159813
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
2.83
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1489748
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
13.82
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
14325377
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1105568
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
5.87
CY2021Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
14325377
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
11163998
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
196976
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
538095
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
810000
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
27.13
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2.19
CY2021Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
0
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-14487132
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-5462047
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7626278
CY2020 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
6308961
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.90
CY2020 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.87
CY2020Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0
CY2020Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
3249815
CY2020 us-gaap State And Local Income Tax Expense Benefit Continuing Operations
StateAndLocalIncomeTaxExpenseBenefitContinuingOperations
0
CY2021 us-gaap State And Local Income Tax Expense Benefit Continuing Operations
StateAndLocalIncomeTaxExpenseBenefitContinuingOperations
0
CY2021 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2020 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2021 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.137
CY2020 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.076
CY2021 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
0.001
CY2020 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
-0.008
CY2021 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Research And Development
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment
0.024
CY2020 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Research And Development
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment
0.019
CY2021 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
0.157
CY2021 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.529
CY2020 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.297
CY2021 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.000
CY2020 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.000
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
6512249
CY2020Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
2460773
CY2021Q4 anvs Deferred Tax Assets Tax Credit Carryforwards Capitalized Research And Development
DeferredTaxAssetsTaxCreditCarryforwardsCapitalizedResearchAndDevelopment
2002431
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
1759129
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
547628
CY2021Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
648077
CY2020Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
241414
CY2021Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
10921886
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
10921886
CY2020Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
3249815
CY2021Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0
CY2021 us-gaap Income Tax Examination Penalties And Interest Expense
IncomeTaxExaminationPenaltiesAndInterestExpense
0
CY2021 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
7672071
CY2020 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
1619516

Files In Submission

Name View Source Status
0001558370-22-002668-index-headers.html Edgar Link pending
0001558370-22-002668-index.html Edgar Link pending
0001558370-22-002668.txt Edgar Link pending
0001558370-22-002668-xbrl.zip Edgar Link pending
anvs-20211231.xsd Edgar Link pending
anvs-20211231x10k.htm Edgar Link pending
anvs-20211231x10k003.jpg Edgar Link pending
anvs-20211231x10k004.jpg Edgar Link pending
anvs-20211231x10k005.jpg Edgar Link pending
anvs-20211231x10k006.jpg Edgar Link pending
anvs-20211231x10k007.jpg Edgar Link pending
anvs-20211231x10k008.jpg Edgar Link pending
anvs-20211231x10k009.jpg Edgar Link pending
anvs-20211231x10k010.jpg Edgar Link pending
anvs-20211231x10k011.jpg Edgar Link pending
anvs-20211231x10k012.jpg Edgar Link pending
anvs-20211231x10k013.jpg Edgar Link pending
anvs-20211231x10k014.jpg Edgar Link pending
anvs-20211231x10k_htm.xml Edgar Link completed
anvs-20211231xex23d1.htm Edgar Link pending
anvs-20211231xex31d1.htm Edgar Link pending
anvs-20211231xex31d2.htm Edgar Link pending
anvs-20211231xex32d1.htm Edgar Link pending
anvs-20211231xex32d2.htm Edgar Link pending
anvs-20211231_cal.xml Edgar Link unprocessable
anvs-20211231_def.xml Edgar Link unprocessable
anvs-20211231_lab.xml Edgar Link unprocessable
anvs-20211231_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending